Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. (1402). Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report. سامانه مدیریت نشریات علمی, 20(4), 466-472. doi: 10.22034/iji.2023.99254.2629
Miao Zhu; Jun Zhang; Qingqing Shi; Xing Sun; Haibo Wang; Mei Sun; Yanqing Liu. "Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report". سامانه مدیریت نشریات علمی, 20, 4, 1402, 466-472. doi: 10.22034/iji.2023.99254.2629
Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. (1402). 'Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report', سامانه مدیریت نشریات علمی, 20(4), pp. 466-472. doi: 10.22034/iji.2023.99254.2629
Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report. سامانه مدیریت نشریات علمی, 1402; 20(4): 466-472. doi: 10.22034/iji.2023.99254.2629

Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report

Iranian Journal of Immunology
مقاله 8، دوره 20، شماره 4، زمستان 2023، صفحه 466-472    اصل مقاله (1.17 M)
نوع مقاله: Case Report
شناسه دیجیتال (DOI): 10.22034/iji.2023.99254.2629
نویسندگان
Miao Zhu1، 2؛ Jun Zhang2؛ Qingqing Shi2؛ Xing Sun2؛ Haibo Wang1؛ Mei Sun2؛ Yanqing Liu* 1
1The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, Jiangsu, China.
2Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
چکیده
Hemophagocytic lymphohistiocytosis (HLH) is a fatal clinical syndrome. The most common cause of secondary HLH is Epstein-Barr virus (EBV) infection. EBV-HLH is a common clinical disease with high mortality, easy relapse, and poor prognosis. Therefore, treating EBV-HLH with T and B lymphocyte involvement is challenging, and selecting an appropriate treatment regimen is critical. Moreover, research on how to evaluate the recurrence index after remission is scarce. In this study, we reported a case of EBV-HLH successfully treated with programmed cell death protein-1 (PD-1) inhibitor in combination with rituximab. The regimen had a good curative effect, and we successfully detected the trend of early recurrence. Our findings indicated that PD-1 inhibitor in combination with rituximab may help to treat EBV-HLH and maintain EBV-infected T and B whole-line lymphocytes.
کلیدواژه‌ها
CD20 Monoclonal Antibody؛ Epstein-Barr Virus؛ Hemophagocytic Lymphohistiocytosis؛ Programmed Cell Death Protein-1؛ Salvage Therapy
مراجع
آمار
تعداد مشاهده مقاله: 1,554
تعداد دریافت فایل اصل مقاله: 1,069